MacroGenics Inc (MGNX) - Total Liabilities
Based on the latest financial reports, MacroGenics Inc (MGNX) has total liabilities worth $201.25 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore MacroGenics Inc annual equity growth to track the company's year-over-year net asset growth rate.
MacroGenics Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how MacroGenics Inc's total liabilities have evolved over time, based on quarterly financial data. See MacroGenics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
MacroGenics Inc Competitors by Total Liabilities
The table below lists competitors of MacroGenics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Signature International Bhd
KLSE:7246
|
Malaysia | RM581.55 Million |
|
SIGA Technologies Inc
NASDAQ:SIGA
|
USA | $67.77 Trillion |
|
Cantor Equity Partners I, Inc. Class A Ordinary Shares
NASDAQ:CEPO
|
USA | $20.04 Million |
|
Thirumalai Chemicals Limited
NSE:TIRUMALCHM
|
India | Rs28.12 Billion |
|
Clarke Inc.
TO:CKI
|
Canada | CA$376.42 Million |
|
ALTEO ENERG.NYIL M.UF125
F:54O
|
Germany | €110.43 Billion |
|
Global Water Resources Inc
NASDAQ:GWRS
|
USA | $391.03 Million |
|
GoldMining Inc
TO:GOLD
|
Canada | CA$10.07 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down MacroGenics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MGNX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MacroGenics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MacroGenics Inc (2011–2025)
The table below shows the annual total liabilities of MacroGenics Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $201.25 Million | +38.23% |
| 2024-12-31 | $145.60 Million | -0.14% |
| 2023-12-31 | $145.81 Million | -1.15% |
| 2022-12-31 | $147.50 Million | +54.24% |
| 2021-12-31 | $95.63 Million | +15.41% |
| 2020-12-31 | $82.86 Million | +1.20% |
| 2019-12-31 | $81.87 Million | -8.27% |
| 2018-12-31 | $89.25 Million | +19.57% |
| 2017-12-31 | $74.64 Million | +75.59% |
| 2016-12-31 | $42.51 Million | -7.45% |
| 2015-12-31 | $45.93 Million | -12.68% |
| 2014-12-31 | $52.60 Million | +12.23% |
| 2013-12-31 | $46.87 Million | -24.39% |
| 2012-12-31 | $61.98 Million | -22.68% |
| 2011-12-31 | $80.16 Million | -- |
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more